{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=26",
    "query": {
      "intervention": "Low Dose Drug A",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:32:42.151Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04780841",
      "title": "A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "RDX013",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardelyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 109,
      "start_date": "2021-01-11",
      "completion_date": "2022-03-03",
      "has_results": false,
      "last_update_posted_date": "2022-05-04",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 6,
      "location_summary": "Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04780841"
    },
    {
      "nct_id": "NCT01939379",
      "title": "Adductor Canal Nerve Block Following Total Knee Arthroplasty",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post-op Pain"
      ],
      "interventions": [
        {
          "name": "Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.",
          "type": "DRUG"
        },
        {
          "name": "For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-09",
      "completion_date": "2017-07-25",
      "has_results": false,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01939379"
    },
    {
      "nct_id": "NCT02822586",
      "title": "TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Sézary Syndrome"
      ],
      "interventions": [
        {
          "name": "TSEB Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2016-12-19",
      "completion_date": "2019-04-29",
      "has_results": false,
      "last_update_posted_date": "2019-08-30",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02822586"
    },
    {
      "nct_id": "NCT04311294",
      "title": "Development of a Selective ALDH2 Inhibitor to Treat AUD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "ANS-6637 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "ANS-6637 High Dose",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-04",
      "completion_date": "2022-03",
      "has_results": false,
      "last_update_posted_date": "2021-05-25",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04311294"
    },
    {
      "nct_id": "NCT06819670",
      "title": "A Study to Prevent Infantile Spasms Relapse",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infantile Spasms",
        "Infantile Epileptic Spasms Syndrome",
        "West Syndrome"
      ],
      "interventions": [
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "18 Months",
        "sex": "ALL",
        "summary": "2 Months to 18 Months"
      },
      "enrollment_count": 40,
      "start_date": "2025-05-05",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819670"
    },
    {
      "nct_id": "NCT04522830",
      "title": "A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "BTL-TML-COVID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beech Tree Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2020-07-30",
      "completion_date": "2021-02-28",
      "has_results": false,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Draper, Utah",
      "locations": [
        {
          "city": "Draper",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04522830"
    },
    {
      "nct_id": "NCT01818011",
      "title": "A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "GSK1322322 Initial fit for purpose tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 over granulated tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 intended commercial tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "DRUG"
        },
        {
          "name": "13C-GSK1322322 stable isotope powder",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 for injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2013-08-07",
      "completion_date": "2013-10-18",
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01818011"
    },
    {
      "nct_id": "NCT00391807",
      "title": "Study of Safety and Efficacy of an Oral Contraceptive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Norethindrone acetate/ethinyl estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 1683,
      "start_date": "2006-11",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2013-04-22",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 66,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00391807"
    },
    {
      "nct_id": "NCT04191681",
      "title": "Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stage D Heart Failure"
      ],
      "interventions": [
        {
          "name": "Sacubitril-Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Usual care (standard-of-care) arm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-11-08",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2021-06-07",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191681"
    },
    {
      "nct_id": "NCT00762892",
      "title": "Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir and truvada",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir, Norvir and Truvada",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2009-01",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2015-01-05",
      "last_synced_at": "2026-11-15T18:32:42.151Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00762892"
    }
  ]
}